DE60226852D1 - Lentivirale verpackungskonstrukte - Google Patents

Lentivirale verpackungskonstrukte

Info

Publication number: DE60226852D1
Authority: DE; Germany
Prior art keywords: cell lines; lentiviral packaging; packaging constructs; lentiviral; present
Prior art date: 2001-03-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60226852T

Other languages

English (en)

Inventor

Tianci Luo

Ivan Plavec

Michael Kaleko

Janet Lynn Douglas

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-13

Filing date

2002-03-13

Publication date

2008-07-10

2002-03-13 Application filed by Novartis AG filed Critical Novartis AG

2008-07-10 Application granted granted Critical

2008-07-10 Publication of DE60226852D1 publication Critical patent/DE60226852D1/de

2022-03-14 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Virology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Packages (AREA)
Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)

DE60226852T 2001-03-13 2002-03-13 Lentivirale verpackungskonstrukte Expired - Lifetime DE60226852D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27527501P	2001-03-13	2001-03-13
PCT/EP2002/002807 WO2002072851A2 (en)	2001-03-13	2002-03-13	Lentiviral packaging constructs

Publications (1)

Publication Number	Publication Date
DE60226852D1 true DE60226852D1 (de)	2008-07-10

Family

ID=23051582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60226852T Expired - Lifetime DE60226852D1 (de)	2001-03-13	2002-03-13	Lentivirale verpackungskonstrukte

Country Status (10)

Country	Link
US (4)	US7070993B2 (de)
EP (2)	EP1373536B9 (de)
JP (1)	JP4413495B2 (de)
AT (1)	ATE397084T1 (de)
CA (1)	CA2439067C (de)
DE (1)	DE60226852D1 (de)
ES (1)	ES2307726T3 (de)
IL (2)	IL157335A0 (de)
NZ (1)	NZ527937A (de)
WO (1)	WO2002072851A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6864085B2 (en) *	1999-12-14	2005-03-08	Novartis Ag	Bovine immunodeficiency virus (BIV) based vectors
CA2435972C (en) *	2001-01-26	2011-09-13	University Of Lausanne	Matrix attachment regions and methods for use thereof
EP1373536B9 (de)	2001-03-13	2009-09-02	Novartis AG	Lentivirale verpackungskonstrukte
AU2003225544A1 (en) *	2002-02-04	2003-09-02	Novartis Ag	Recombinant bovine immunodeficiency virus based gene transfer system
EP1959011B1 (de)	2003-10-24	2012-03-28	Selexis S.A.	Gentransfer und Expression mit hoher Effizienz in Säugerzellen mittels eines Mehrfachtransfektionsverfahrens von Matrixbindungsbereichsequenzen
US7135339B2 (en) *	2003-11-20	2006-11-14	University Of Iowa Research Foundation	Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2007109131A2 (en) *	2006-03-17	2007-09-27	Massachusetts Institute Of Technology	Lentiviral vectors that provide improved expression and reduced variegation after transgenesis
WO2010127166A2 (en)	2009-04-30	2010-11-04	The Regents Of The University Of California	Combination anti-hiv vectors, targeting vectors, and methods of use
AU2011230619C1 (en)	2010-03-25	2016-06-23	Oregon Health & Science University	CMV glycoproteins and recombinant vectors
ES2667425T3 (es)	2011-06-10	2018-05-10	Oregon Health & Science University	Glucoproteínas y vectores recombinantes de CMV
GB201202516D0 (en)	2012-02-13	2012-03-28	Ucl Business Plc	Materials and methods relating to packaging cell lines
US20140011980A1 (en) *	2012-07-03	2014-01-09	Allergan, Inc.	Methods for sterilizing compositions and resulting compositions
US20150283266A1 (en)	2012-08-09	2015-10-08	The Regents Of The University Of California	Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
US20140065110A1 (en)	2012-08-31	2014-03-06	The Regents Of The University Of California	Genetically modified msc and therapeutic methods
DE102013004595A1 (de)	2013-03-15	2014-09-18	Emergent Product Development Germany Gmbh	RSV-Impfstoffe
WO2016160618A2 (en)	2015-03-27	2016-10-06	University Of Southern California	Car t-cell therapy directed to lhr for the treatment of solid tumors
GB201509040D0 (en) *	2015-05-27	2015-07-08	Oxford Genetics Ltd	Cell lines
CN107847601A (zh)	2015-06-04	2018-03-27	南加利福尼亚大学	Lym‑1和lym‑2靶向的car细胞免疫疗法
WO2017053889A2 (en)	2015-09-23	2017-03-30	Precision Immunotherapy, Inc.	Flt3 directed car cells for immunotherapy
CA3110905A1 (en)	2018-08-31	2020-03-05	Invectys SA	Chimeric antigen receptors against multiple hla-g isoforms
US11912986B2 (en)	2019-09-23	2024-02-27	The Regents Of The University Of California	Methods for screening genetic perturbations
IL297236A (en)	2020-04-17	2022-12-01	Hope City	Cells modified with a flt3-specific chimeric antigen receptor for the treatment of flt3-positive cancers
GB202102832D0 (en) *	2021-02-26	2021-04-14	Ip2Ipo Innovations Ltd	Retroviral vectors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5380830A (en) *	1989-09-18	1995-01-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Molecular clones of bovine immunodeficiency-like virus
ATE188740T1 (de)	1991-02-19	2000-01-15	Univ California	Viruspartikel mit veraendertem wirtspektrum
WO1994011524A1 (en)	1992-11-09	1994-05-26	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Targetable vector particles
US5498537A (en) *	1994-03-09	1996-03-12	Cellco, Inc.	Serum-free production of packaged viral vector
US5888774A (en)	1994-12-19	1999-03-30	Cangene Corporation	Recombinant DNA molecules and expression vectors for erythropoietin
CA2256484A1 (en)	1996-06-06	1997-12-11	Novartis Ag	Vectors comprising sar elements
JP2001513643A (ja) *	1997-03-06	2001-09-04	ウーベルラ、クラウス	レンチウイルスをベースとするベクター及びベクター系
US6207455B1 (en) *	1997-05-01	2001-03-27	Lung-Ji Chang	Lentiviral vectors
IL132463A0 (en)	1997-05-13	2001-03-19	Univ North Carolina	Lentivirus - based gene transfer vectors
US6004798A (en)	1997-05-14	1999-12-21	University Of Southern California	Retroviral envelopes having modified hypervariable polyproline regions
US5994136A (en) *	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1045921A2 (de) *	1998-01-16	2000-10-25	Chiron Corporation	Vom immunschwächevirus der katze (fiv) abgeleiteten gentherapievektoren
US6958226B1 (en) *	1998-09-11	2005-10-25	The Children's Medical Center Corp.	Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
US7329728B1 (en)	1999-10-25	2008-02-12	The Scripps Research Institute	Ligand activated transcriptional regulator proteins
AU778110B2 (en)	1999-12-14	2004-11-18	Novartis Ag	Bovine immunodeficiency virus (BIV) based vectors
US6864085B2 (en) *	1999-12-14	2005-03-08	Novartis Ag	Bovine immunodeficiency virus (BIV) based vectors
US20110097709A1 (en)	2000-03-13	2011-04-28	Kidd Geoffrey L	Method for modifying a nucleic acid
EP1908835A3 (de)	2000-07-18	2008-06-18	Novartis AG	Regulierung von Genexpression durch einkettige, monomere, ligandenabhängige Polypeptidschalter
EP1373536B9 (de) *	2001-03-13	2009-09-02	Novartis AG	Lentivirale verpackungskonstrukte
AU2003225544A1 (en) *	2002-02-04	2003-09-02	Novartis Ag	Recombinant bovine immunodeficiency virus based gene transfer system

2002
- 2002-03-13 EP EP02704755A patent/EP1373536B9/de not_active Expired - Lifetime
- 2002-03-13 AT AT02704755T patent/ATE397084T1/de active
- 2002-03-13 ES ES02704755T patent/ES2307726T3/es not_active Expired - Lifetime
- 2002-03-13 IL IL15733502A patent/IL157335A0/xx not_active IP Right Cessation
- 2002-03-13 EP EP08009240A patent/EP1967590A3/de not_active Withdrawn
- 2002-03-13 CA CA2439067A patent/CA2439067C/en not_active Expired - Fee Related
- 2002-03-13 DE DE60226852T patent/DE60226852D1/de not_active Expired - Lifetime
- 2002-03-13 WO PCT/EP2002/002807 patent/WO2002072851A2/en active IP Right Grant
- 2002-03-13 NZ NZ527937A patent/NZ527937A/en not_active IP Right Cessation
- 2002-03-13 US US10/097,002 patent/US7070993B2/en not_active Expired - Lifetime
- 2002-03-13 JP JP2002571902A patent/JP4413495B2/ja not_active Expired - Fee Related
2006
- 2006-06-30 US US11/428,118 patent/US7442551B2/en not_active Expired - Fee Related
- 2006-06-30 US US11/428,092 patent/US7700342B2/en not_active Expired - Fee Related
2007
- 2007-02-05 US US11/671,212 patent/US8183356B2/en not_active Expired - Fee Related
- 2007-08-09 IL IL185142A patent/IL185142A0/en unknown

Also Published As

Publication number	Publication date
US20080268522A1 (en)	2008-10-30
JP4413495B2 (ja)	2010-02-10
US8183356B2 (en)	2012-05-22
EP1373536B9 (de)	2009-09-02
EP1967590A2 (de)	2008-09-10
US20070010017A1 (en)	2007-01-11
US7700342B2 (en)	2010-04-20
US20080021207A1 (en)	2008-01-24
CA2439067A1 (en)	2002-09-19
ES2307726T3 (es)	2008-12-01
IL157335A0 (en)	2004-02-19
NZ527937A (en)	2005-03-24
ATE397084T1 (de)	2008-06-15
EP1373536A2 (de)	2004-01-02
US7442551B2 (en)	2008-10-28
IL185142A0 (en)	2009-02-11
WO2002072851A2 (en)	2002-09-19
JP2004523242A (ja)	2004-08-05
US20030054548A1 (en)	2003-03-20
EP1967590A3 (de)	2008-09-17
US7070993B2 (en)	2006-07-04
WO2002072851A3 (en)	2003-10-30
AU2002238584B2 (en)	2006-02-23
CA2439067C (en)	2011-02-15
EP1373536B1 (de)	2008-05-28

Publication	Publication Date	Title
IL185142A0 (en)	2009-02-11	Lentiviral packaging constructs
TW200611910A (en)	2006-04-16	Interferon-alpha polypeptides and conjugates
WO2006083276A3 (en)	2009-04-16	Interferon-alpha polypeptides and conjugates
BRPI0412402A (pt)	2006-09-05	polipeptìdeos de amilase termoestáveis, ácidos nucléicos codificando esses polipeptìdeos e seus usos
IL172854A0 (en)	2006-06-11	Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
CY1112101T1 (el)	2015-11-04	Νευροτροφικοι παραγοντες
DK1210411T3 (da)	2007-02-19	Sammensætninger og fremgangsmåder til forbedret celledyrkning
DE602004013372D1 (de)	2008-06-05	Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
MA30153B1 (fr)	2009-01-02	Anticorps anti-ox40l et methodes correspondantes
DK1450847T3 (da)	2010-12-13	Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
CY1110225T1 (el)	2015-01-14	Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
TR200202194T2 (tr)	2003-01-21	Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE293159T1 (de)	2005-04-15	Stabilisierendes verdünnungsmittel für polypeptide und antigene
AU3281902A (en)	2002-07-01	Methods for the production of multimeric proteins, and related compositions
WO2001049728A3 (en)	2002-03-14	HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2004046365A3 (en)	2004-09-02	Interferon-alpha polypeptides and conjugates
AU2002232819A1 (en)	2002-09-05	Methods for the production of multimeric proteins, and related compositions
CY1118782T1 (el)	2017-07-12	Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
WO2003104425A3 (en)	2005-02-17	NEW STABLE ANTI-CD22 ANTIBODIES
ATE411086T1 (de)	2008-10-15	Verwendung von granulaten in kosmetischen zusammensetzungen auf basis von pyrogenisch hergestelltem siliziumdioxid
NO992916D0 (no)	1999-06-15	Fosfodiesterase 8A
ATE309356T1 (de)	2005-11-15	Konstruierte fluoreszenzproteine mit langen wellenlängen
TR200402030T4 (tr)	2004-09-21	İkame edilen I-aminobutan-3-ol-türevleri
ATE557034T1 (de)	2012-05-15	Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen

Legal Events

Date	Code	Title	Description
2009-06-18	8364	No opposition during term of opposition